Recognition and management of complications of new recreational drug use

Use of illicit drugs in clubs and large dance parties (so-called raves) is a burgeoning cultural trend. Such recreational drug use is associated with several medical complications, both acute and longlasting. Although few, if any, of the drugs currently used in recreational venues are truly new, their patterns and context of use have changed (a great deal in some instances). For some of these substances, this cultural repackaging of the drug experience has resulted in various medical disorders that have previously gone undocumented. This review aims to help treating physicians recognise and manage complications associated with the use of new drugs in clubs, including methylenedioxymethamfetamine, ephedrine, gamma-hydroxybutyrate; gamma-butyrolactone, 1,4-butanediol, flunitrazepam, ketamine, and nitrites. We also alert researchers to specific toxic effects of club-drugs on which more basic information is needed.

[1]  Patrick M. O'Malley,et al.  Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2004. , 2003 .

[2]  Paul J. Wang,et al.  Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. , 2002, Mayo Clinic proceedings.

[3]  J. Olney,et al.  NMDA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia , 1995, Neuropsychopharmacology.

[4]  A. Giannini,et al.  Acute ketamine intoxication treated by haloperidol: a preliminary study. , 2000, American journal of therapeutics.

[5]  H. Kalant,et al.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[6]  M. Aminoff.  Neurology and General Medicine , 2007 .

[7]  K. Miotto,et al.  Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. , 2001, The American journal on addictions.

[8]  H. Druid,et al.  Flunitrazepam: an evaluation of use, abuse and toxicity. , 2001, Forensic science international.

[9]  R. de la Torre,et al.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.

[10]  M. J. Cupp,et al.  Use and Abuse of Flunitrazepam , 1998, The Annals of pharmacotherapy.

[11]  A. Weinbroum,et al.  A Risk-Benefit Assessment of Flumazenil in the Management of Benzodiazepine Overdose , 1997, Drug safety.

[12]  J. Kraner,et al.  Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). , 2001, Journal of analytical toxicology.

[13]  Liesbeth Reneman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[14]  M. Colado,et al.  The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.

[15]  L. Quang,et al.  Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. , 2000, Pediatric emergency care.

[16]  Jones,et al.  Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications , 1999, Alimentary pharmacology & therapeutics.

[17]  M. Spitz,et al.  Volatile nitrites. Use and adverse effects related to the current epidemic of the acquired immune deficiency syndrome. , 1985, The American journal of medicine.

[18]  D. Aunis,et al.  Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator γ‐hydroxybutyrate , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  B. Goldberger,et al.  Recreational drugs. Current trends in the 90s. , 1998, Clinics in laboratory medicine.

[20]  H. Pal,et al.  Ketamine dependence. , 2002, Anaesthesia and intensive care.

[21]  F. Romanelli,et al.  Poppers: Epidemiology and Clinical Management of Inhaled Nitrite Abuse , 2004, Pharmacotherapy.

[22]  R. Hoffman,et al.  The “ecstasy” hangover: Hyponatremia due to 3,4-Methylenedioxymethamphetamine , 2002, Journal of Urban Health.

[23]  M. Shannon.  Methylenedioxymethamphetamine (MDMA, "Ecstasy"). , 2000, Pediatric emergency care.

[24]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies , 2000, Neuropsychobiology.

[25]  G. Galloway,et al.  Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. , 1997, Addiction.

[26]  K. Graeme.  New drugs of abuse. , 2000, Emergency medicine clinics of North America.

[27]  C. McKay,et al.  Ketamine abusers presenting to the emergency department: a case series. , 2000, The Journal of emergency medicine.

[28]  R. Clark,et al.  A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. , 2001, The Journal of emergency medicine.

[29]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.

[30]  J. Dyer,et al.  Gamma-hydroxybutyrate withdrawal syndrome. , 2001, Annals of emergency medicine.

[31]  Retraction Kiehntopf,et al.  Retraction , 1997, Concurr. Comput. Pract. Exp..

[32]  K. Jansen,et al.  The Nonmedical Use of Ketamlne, Part Two: A Review of Problent Use and Dependence , 2001, Journal of psychoactive drugs.

[33]  N. Benowitz,et al.  Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids , 2000 .

[34]  M. Parr,et al.  Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. , 2002, QJM : monthly journal of the Association of Physicians.

[35]  M. Forsling,et al.  Low-dose MDMA (“ecstasy”) induces vasopressin secretion , 1998, The Lancet.

[36]  G. Goodwin,et al.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) , 1995, Psychopharmacology.

[37]  A. Mallick,et al.  MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. , 1997, Journal of accident & emergency medicine.

[38]  J. Li,et al.  Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. , 2000, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[39]  F. Romanelli,et al.  Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[40]  P. Rogers,et al.  MDMA ('ecstasy') and other 'club drugs'. The new epidemic. , 2002, Pediatric clinics of North America.

[41]  C. Morgan,et al.  Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. , 2000, Addiction.

[42]  K. Nicholson,et al.  GHB: a new and novel drug of abuse. , 2001, Drug and alcohol dependence.

[43]  Stephen W. Smith,et al.  Adverse events, including death, associated with the use of 1,4-butanediol. , 2001, The New England journal of medicine.

[44]  E. Guérot,et al.  Acute benzodiazepine withdrawal delirium after a short course of flunitrazepam in an intensive care patient. , 2000, Annales de medecine interne.

[45]  S. Dawling,et al.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.

[46]  J. Woods,et al.  Abuse liability of flunitrazepam. , 1997, Journal of clinical psychopharmacology.

[47]  B. O'Connor.  Hazards associated with the recreational drug 'ecstasy'. , 1994, British journal of hospital medicine.

[48]  M. Sivilotti,et al.  Pentobarbital for severe gamma-butyrolactone withdrawal. , 2001, Annals of emergency medicine.

[49]  J. Knochel,et al.  Medical progress: Heat stroke , 2002 .

[50]  S. Doyon.  The many faces of ecstasy. , 2001, Current opinion in pediatrics.

[51]  M. Verbaten.  Specific memory deficits in ecstasy users? The results of a meta‐analysis , 2003, Human psychopharmacology.

[52]  L. Johnston,et al.  Monitoring the Future National Survey Results on Drug Use, 1975-2001. Volume 1: Secondary School Students, 2001. , 2002 .

[53]  W. Lynn,et al.  Gamma butyrolactone (GBL) withdrawal syndromes. , 2001, Psychosomatics.

[54]  Metaphors, Misuse, and Misconceptions , 2003, Science.